Advertisement
Screener

Ovid Therapeutics Inc. (OVID) Other

Ovid Therapeutics Inc. Other

Cover page items of the 10-K and 10-Q that have no other home: a security other than the listed stock or a bond, a check box that differs from the latest cover, or a figure not in the Balance Sheet › Equity tabs. Newest first, as filed.

  • 2025-03-11: Form 10-K; Item Shares outstanding as of 2025-03-07; As filed 71,075,005.
  • 2022-11-08: Form 10-Q; Item Emerging growth company; As filed Yes.
  • 2022-08-09: Form 10-Q; Item Emerging growth company; As filed Yes.
  • 2022-05-10: Form 10-Q; Item Emerging growth company; As filed Yes.
FiledFormItemAs filed
2025-03-1110-KShares outstanding as of 2025-03-0771,075,005
2022-11-0810-QEmerging growth companyYes
2022-08-0910-QEmerging growth companyYes
2022-05-1010-QEmerging growth companyYes
2022-03-1510-KEmerging growth companyYes
2021-11-1010-QEmerging growth companyYes
2021-08-1610-QEmerging growth companyYes
2021-05-1310-QEmerging growth companyYes
2021-03-1510-KEmerging growth companyYes
2020-11-1310-QEmerging growth companyYes
2020-08-1010-QEmerging growth companyYes
2020-05-0710-QEmerging growth companyYes
2020-03-1110-KEmerging growth companyYes
2019-11-0810-QEmerging growth companyYes
2019-08-0710-QEmerging growth companyYes
2019-05-0710-QEmerging growth companyYes
2019-03-0710-KEmerging growth companyYes
2018-11-0810-QSmaller reporting companyNo
2018-11-0810-QEmerging growth companyYes

Similar stocks

Stock NameCountryMarket CapPE Ratio
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53
ARVINAS, INC. (ARVN)United States$0.510B58.38
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Evolus, Inc. (EOLS)United States$0.519B-13.32
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63
Indaptus Therapeutics, Inc. (INDP)United States$0.537B